Vertex Pharmaceuticals (VRTX) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Vertex Pharmaceuticals · Health Care · ref. ETF XLV · 95 calls · price $485.22
What the company does: Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
📈 Vertex Pharmaceuticals (VRTX) stock price
$485.22+17.7% over range
Oct 14, 25low $407.9 · high $557.96Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
80% recommend buying · 10 analysts
📊 JPI status : Vertex Pharmaceuticals is no longer in our current JPI rankings, but appeared in the past (2017) — its upside may be behind it. See the stocks picked in 2017 →
🎯 VRTX price target & analyst consensus — price $485
The price target · all analysts combined (10 targets)
Highest target · 1 firm of 10$617+27.2%
Median target · of 10 targets$574+18.3%
Lowest target · 1 firm of 10$350-27.9%
Current price$485.22
Where these 10 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
880%
$550 ↔ $617
Below
220%
$350 ↔ $442
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: UBS — 66% of its targets hit on this sector (358 calls tested). It aims for $615 (+27 %), call made on September 29, 2026, maturing on September 29, 2027 (15 d ago).
The 5 reliable analysts
$565+16 %
The 5 other firms
$576+19 %
How to read it: the 5 reliable firms are not filtered by optimism — 4 aim above the price, 1 below, hence their $565 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 10 ratings (last 6 months)
Strong Buy00%
Buy880%
Hold110%
Sell110%
Strong Sell00%
Go deeper on the analysts
🎯 VRTX price target all
All 95 calls, one by one, with our verdict on each firm.
→ See all 95 targets, analyst by analyst💡 The best analysts on VRTX most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in VRTX? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Vertex Pharmaceuticals? The JPI assistant answers using our backtest data.
📈 Vertex Pharmaceuticals fundamentals: valuation, margins & growth › open the full page
P/E 28.3Net margin 35.0 %Revenue growth +12.5 %Average P/E
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 37 %
2023
Rev +11%Profit +9%
2024
Rev +12%Profit −115%
2025
Rev +9%
🔎 Detailed analyses
✅ Historical analyst reliability on VRTX
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Janney Montgomery Scott | 100% | +37.7% | 2 |
| Baird ↗ | 100% | +33.8% | 8 |
| Evercore ISI Group ↗ | 100% | +30.1% | 11 |
| Cowen & Co. | 100% | +26.1% | 2 |
| William Blair ↗ | 100% | +23.1% | 2 |
| Maxim Group | 100% | +14.8% | 3 |
| Raymond James ↗ | 100% | +13.6% | 2 |
| Piper Sandler ↗ | 90% | +16.7% | 10 |
| Wells Fargo ↗ | 89% | +24.2% | 9 |
| BMO Capital ↗ | 86% | +20.6% | 14 |
See the other 26 firms
| Canaccord Genuity ↗ | 33% | -9.8% | 6 |
| SunTrust Robinson Humphrey | 50% | -13.9% | 2 |
| CFRA | 50% | -7.0% | 2 |
| Stifel ↗ | 50% | -0.3% | 8 |
| SVB Leerink | 50% | +0.5% | 4 |
| Citigroup ↗ | 53% | +7.6% | 15 |
| Morgan Stanley ↗ | 54% | +3.8% | 13 |
| Argus Research ↗ | 57% | +11.0% | 7 |
| Credit Suisse | 58% | +12.6% | 12 |
| JMP Securities | 60% | +15.7% | 5 |
| Cantor Fitzgerald ↗ | 63% | +11.8% | 30 |
| Leerink Swann | 67% | -6.1% | 3 |
| B of A Securities ↗ | 67% | +12.2% | 12 |
| Jefferies ↗ | 67% | +31.5% | 6 |
| JP Morgan ↗ | 71% | +9.9% | 14 |
| Goldman Sachs ↗ | 71% | +10.0% | 7 |
| Guggenheim ↗ | 71% | +17.3% | 7 |
| RBC Capital ↗ | 73% | +17.3% | 15 |
| Barclays ↗ | 74% | +14.8% | 19 |
| UBS ↗ | 74% | +18.4% | 19 |
| Oppenheimer ↗ | 75% | +12.3% | 12 |
| HC Wainwright & Co. ↗ | 77% | +15.8% | 26 |
| Truist Securities ↗ | 80% | +14.0% | 10 |
| TD Cowen ↗ | 80% | +20.4% | 5 |
| Bernstein ↗ | 80% | +23.7% | 5 |
| Deutsche Bank ↗ | 83% | +29.0% | 6 |
📊 What $1,000 invested in Vertex Pharmaceuticals would be worth › open the full page
In short — $1,000 invested in Vertex Pharmaceuticals 10 years ago would be worth $3,948 today, i.e. +15%/yr on average. Best year: 2017 (+103%), worst: 2016 (-41%). Price performance, excluding dividends.
If I'd invested $1,000 in Vertex Pharmaceuticals
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,233 | +23% |
| 3 years ago | $1,720 | +72% |
| 5 years ago | $2,102 | +110% |
Return by year (Vertex Pharmaceuticals)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +10% | $1,096 (+10%) |
| 2025 | +13% | $1,233 (+23%) |
| 2024 | -1% | $1,221 (+22%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Vertex Pharmaceuticals
Loading news…
📋 All analyst calls on VRTX
Filtered on — · ✕ show all
RBC Capital ↗
Oct 8, 26
▲ Outperform · 🎯$576
Price at call : $510.08 — upside +13%
Today : $485.22 — upside +19%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Oct 8, 27
matures : Oct 8, 27
▲ Buy · 🎯$615
Price at call : $526.73 — upside +17%
Today : $485.22 — upside +27%
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Sep 28, 27
matures : Sep 28, 27
Truist Securities ↗
Aug 5, 26
▲ Buy · 🎯$565
Price at call : $484.03 — upside +17%
Today : $485.22 — upside +16%
🎯 on VRTX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
▲ Overweight · 🎯$617
Price at call : $484.03 — upside +27%
Today : $485.22 — upside +27%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
▲ Buy · 🎯$550
Price at call : $484.83 — upside +13%
Today : $485.22 — upside +13%
🎯 on VRTX : no call matured yet · 📊 on Health : 48% · +0.6% (98 calls)
in progress (365j)
matures : Aug 4, 27
matures : Aug 4, 27
Cantor Fitzgerald ↗
Aug 4, 26
▲ Overweight · 🎯$595
Price at call : $478.71 — upside +24%
Today : $485.22 — upside +23%
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
in progress (365j)
matures : Aug 4, 27
matures : Aug 4, 27
Canaccord Genuity ↗
Aug 4, 26
■ Hold neutral · not a buy · 🎯$442
Price at call : $478.71 — gap to target -8%
Today : $485.22 — gap to target -9%
🎯 on VRTX : no call matured yet · 📊 on Health : 52.6% · +5.0% (154 calls)
in progress (365j)
matures : Aug 4, 27
matures : Aug 4, 27
▲ Buy · 🎯$585
Price at call : $476.31 — upside +23%
Today : $485.22 — upside +21%
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
See the other 87 calls, newest to oldest
Truist Securities ↗
Jul 13, 26
▲ Buy · 🎯$560
Price at call : $476.31 — upside +18%
Today : $485.22 — upside +15%
🎯 on VRTX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
RBC Capital ↗
Jul 7, 26
▲ Outperform · 🎯$570
Price at call : $498.43 — upside +14%
Today : $485.22 — upside +17%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
▼ Underperform · 🎯$350
Price at call : $522.25 — upside -33%
Today : $485.22 — upside -28%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Jul 7, 27
matures : Jul 7, 27
▲ Overweight · 🎯$615
Price at call : $425 — upside +45%
Today : $485.22 — upside +27%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
Canaccord Genuity ↗
May 5, 26
■ Hold neutral · not a buy · 🎯$436
Price at call : $427.65 — gap to target +2%
Today : $485.22 — gap to target -10%
🎯 on VRTX : no call matured yet · 📊 on Health : 52.6% · +5.0% (154 calls)
in progress (365j)
matures : May 5, 27
matures : May 5, 27
Morgan Stanley ↗
May 5, 26
▲ Overweight · 🎯$616
Price at call : $427.65 — upside +44%
Today : $485.22 — upside +27%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : May 5, 27
matures : May 5, 27
▲ Outperform · 🎯$572
Price at call : $427.65 — upside +34%
Today : $485.22 — upside +18%
🎯 on VRTX : no call matured yet · 📊 on Health : 55.7% · +5.7% (70 calls)
in progress (365j)
matures : May 5, 27
matures : May 5, 27
RBC Capital ↗
May 5, 26
▲ Outperform · 🎯$543
Price at call : $427.65 — upside +27%
Today : $485.22 — upside +12%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : May 5, 27
matures : May 5, 27
Canaccord Genuity ↗
May 1, 26
■ Hold neutral · not a buy · 🎯$437
Price at call : $423.92 — gap to target +3%
Today : $485.22 — gap to target -10%
🎯 on VRTX : no call matured yet · 📊 on Health : 52.6% · +5.0% (154 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
Morgan Stanley ↗
Apr 10, 26
▲ Overweight · 🎯$612
Price at call : $440.05 — upside +39%
Today : $485.22 — upside +26%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Apr 10, 27
matures : Apr 10, 27
Maxim Group
Mar 18, 26
▲ Buy · 🎯$575
Price at call : $458.05 — upside +26%
Today : $485.22 — upside +19%
🎯 on VRTX : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Mar 18, 27
matures : Mar 18, 27
Truist Securities ↗
Mar 11, 26
▲ Buy · 🎯$525
Price at call : $478.13 — upside +10%
Today : $485.22 — upside +8%
🎯 on VRTX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Mar 11, 27
matures : Mar 11, 27
Morgan Stanley ↗
Mar 10, 26
▲ Overweight · 🎯$596
Price at call : $492.38 — upside +21%
Today : $485.22 — upside +23%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Mar 10, 27
matures : Mar 10, 27
B of A Securities ↗
Mar 10, 26
▲ Buy · 🎯$598
Price at call : $492.38 — upside +21%
Today : $485.22 — upside +23%
🎯 on VRTX : no call matured yet · 📊 on Health : 48.1% · +2.0% (362 calls)
in progress (365j)
matures : Mar 10, 27
matures : Mar 10, 27
▲ Buy · 🎯$585
Price at call : $492.38 — upside +19%
Today : $485.22 — upside +21%
🎯 on VRTX : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Mar 10, 27
matures : Mar 10, 27
Oppenheimer ↗
Mar 10, 26
▲ Outperform · 🎯$600
Price at call : $492.38 — upside +22%
Today : $485.22 — upside +24%
🎯 on VRTX : no call matured yet · 📊 on Health : 43.5% · -0.2% (223 calls)
in progress (365j)
matures : Mar 10, 27
matures : Mar 10, 27
▲ Buy · 🎯$580
Price at call : $492.38 — upside +18%
Today : $485.22 — upside +20%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.2% · +4.7% (383 calls)
in progress (365j)
matures : Mar 10, 27
matures : Mar 10, 27
HC Wainwright & Co. ↗
Mar 10, 26
▲ Buy · 🎯$641
Price at call : $499.17 — upside +28%
Today : $485.22 — upside +32%
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Mar 10, 27
matures : Mar 10, 27
Canaccord Genuity ↗
Feb 17, 26
■ Hold neutral · not a buy · 🎯$441
Price at call : $470.31 — gap to target -6%
Today : $485.22 — gap to target -9%
🎯 on VRTX : no call matured yet · 📊 on Health : 52.6% · +5.0% (154 calls)
in progress (365j)
matures : Feb 17, 27
matures : Feb 17, 27
▲ Overweight · 🎯$607
Price at call : $470.31 — upside +29%
Today : $485.22 — upside +25%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Feb 17, 27
matures : Feb 17, 27
HC Wainwright & Co. ↗
Feb 17, 26
▲ Buy · 🎯$591
Price at call : $477.32 — upside +24%
Today : $485.22 — upside +22%
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Feb 17, 27
matures : Feb 17, 27
Scotiabank ↗
Feb 13, 26
■ Sector Perform neutral · not a buy · 🎯$558
Price at call : $477.32 — gap to target +17%
Today : $485.22 — gap to target +15%
🎯 on VRTX : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Feb 13, 27
matures : Feb 13, 27
RBC Capital ↗
Feb 13, 26
▲ Outperform · 🎯$541
Price at call : $477.32 — upside +13%
Today : $485.22 — upside +11%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Feb 13, 27
matures : Feb 13, 27
■ Hold neutral · not a buy · 🎯$466
Price at call : $477.32 — gap to target -2%
Today : $485.22 — gap to target -4%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Feb 13, 27
matures : Feb 13, 27
Oppenheimer ↗
Feb 13, 26
▲ Outperform · 🎯$540
Price at call : $477.32 — upside +13%
Today : $485.22 — upside +11%
🎯 on VRTX : no call matured yet · 📊 on Health : 43.5% · -0.2% (223 calls)
in progress (365j)
matures : Feb 13, 27
matures : Feb 13, 27
HC Wainwright & Co. ↗
Feb 13, 26
▲ Buy · 🎯$518
Price at call : $491.47 — upside +5%
Today : $485.22 — upside +7%
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
in progress (365j)
matures : Feb 13, 27
matures : Feb 13, 27
▲ Overweight · 🎯$606
Price at call : $475.68 — upside +27%
Today : $485.22 — upside +25%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Jan 28, 27
matures : Jan 28, 27
▲ Buy · 🎯$545
Price at call : $474.17 — upside +15%
Today : $485.22 — upside +12%
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Jan 26, 27
matures : Jan 26, 27
Evercore ISI Group ↗
Jan 23, 26
▲ Outperform · 🎯$530
Price at call : $468.41 — upside +13%
Today : $485.22 — upside +9%
🎯 on VRTX : no call matured yet · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Jan 23, 27
matures : Jan 23, 27
RBC Capital ↗
Jan 22, 26
▲ Outperform · 🎯$546
Price at call : $468.41 — upside +17%
Today : $485.22 — upside +13%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
▲ Outperform
🎯 on VRTX : no call matured yet · 📊 on Health : 55.7% · +5.7% (70 calls)
in progress (365j)
matures : Jan 12, 27
matures : Jan 12, 27
Wolfe Research ↗
Jan 6, 26
▲ Outperform · 🎯$548
Price at call : $468.38 — upside +17%
Today : $485.22 — upside +13%
🎯 on VRTX : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Jan 6, 27
matures : Jan 6, 27
Leerink Partners ↗
Dec 29, 25
▲ Outperform · 🎯$525
Price at call : $459.78 — upside +14%
Today : $485.22 — upside +8%
🎯 on VRTX : 100% (1 call matured) · 📊 on Health : 53.7% · -6.2% (41 calls)
in progress (365j)
matures : Dec 29, 26
matures : Dec 29, 26
Wells Fargo ↗
Dec 10, 25
▲ Overweight · 🎯$515
Price at call : $445.93 — upside +15%
Today : $485.22 — upside +6%
🎯 on VRTX : no call matured yet · 📊 on Health : 47.6% · +1.0% (403 calls)
in progress (365j)
matures : Dec 10, 26
matures : Dec 10, 26
Morgan Stanley ↗
Dec 5, 25
▲ Overweight · 🎯$564
Price at call : $442.04 — upside +28%
Today : $485.22 — upside +16%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Dec 5, 26
matures : Dec 5, 26
Morgan Stanley ↗
Dec 3, 25
▲ Overweight · 🎯$516
Price at call : $457.36 — upside +13%
Today : $485.22 — upside +6%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Dec 3, 26
matures : Dec 3, 26
▲ Buy · 🎯$546
Price at call : $421.2 — upside +30%
Today : $485.22 — upside +13%
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Nov 7, 26
matures : Nov 7, 26
RBC Capital ↗
Nov 4, 25
■ Sector Perform neutral · not a buy · 🎯$415
Price at call : $417 — gap to target -0%
Today : $485.22 — gap to target -14%
🎯 on VRTX : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Nov 4, 26
matures : Nov 4, 26
■ Equal-Weight neutral · not a buy · 🎯$414
Price at call : $421.67 — gap to target -2%
Today : $485.22 — gap to target -15%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Nov 4, 26
matures : Nov 4, 26
■ Hold neutral · not a buy · 🎯$445
Price at call : $421.67 — gap to target +6%
Today : $485.22 — gap to target -8%
🎯 on VRTX : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Nov 4, 26
matures : Nov 4, 26
Morgan Stanley ↗
Oct 10, 25
■ Equal-Weight neutral · not a buy · 🎯$438
Price at call : $407.37 — gap to target +8%
Today : $485.22 — gap to target -10%
🎯 on VRTX : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Oct 10, 26
matures : Oct 10, 26
▲ Overweight · 🎯$530
Price at call : $414.86 — upside +28%
Today : $485.22 — upside +9%
Expected +28% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 100% (1 call matured) · 📊 on Health : 53.8% · +5.2% (364 calls)
+22.9%
stock +23% · XLV +18%
matured Oct 8, 26
Leerink Partners ↗
Sep 25, 25
▲ Outperform · 🎯$456
Price at call : $381.87 — upside +19%
Today : $485.22 — upside -6%
Expected +19% · Actual +38% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 100% (1 call matured) · 📊 on Health : 53.7% · -6.2% (41 calls)
+37.8%
stock +38% · XLV +27%
matured Sep 25, 26
▲ Buy · 🎯$553
Price at call : $385.65 — upside +43%
Today : $485.22 — upside +14%
Expected +43% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+25.5%
stock +26% · XLV +26%
matured Aug 5, 26
Cantor Fitzgerald ↗
Aug 5, 25
▲ Overweight · 🎯$485
Price at call : $374.98 — upside +29%
Today : $485.22 — upside -0%
Expected +29% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
+29.3%
stock +29% · XLV +24%
matured Aug 5, 26
HC Wainwright & Co. ↗
Aug 5, 25
▲ Buy · 🎯$478
Price at call : $374.98 — upside +27%
Today : $485.22 — upside -1%
Expected +27% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+29.3%
stock +29% · XLV +24%
matured Aug 5, 26
HC Wainwright & Co. ↗
Jun 23, 25
▲ Buy · 🎯$550
Price at call : $443.54 — upside +24%
Today : $485.22 — upside +13%
Expected +24% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+5.6%
stock +6% · XLV +15%
matured Jun 23, 26
Cantor Fitzgerald ↗
May 6, 25
▲ Overweight · 🎯$535
Price at call : $450.03 — upside +19%
Today : $485.22 — upside +10%
Expected +19% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-5.0%
stock -5% · XLV +8%
matured May 6, 26
Leerink Partners ↗
May 6, 25
■ Market Perform neutral · not a buy · 🎯$503
Price at call : $450.03 — gap to target +12%
Today : $485.22 — gap to target +4%
🎯 on VRTX : 100% (1 call matured) · 📊 on Health : 53.7% · -6.2% (41 calls)
in progress (365j)
matures : May 6, 26
matures : May 6, 26
▲ Buy · 🎯$583
Price at call : $453.2 — upside +29%
Today : $485.22 — upside +20%
Expected +29% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+2.6%
stock +3% · XLV +7%
matured Feb 11, 26
Cantor Fitzgerald ↗
Feb 11, 25
▲ Overweight · 🎯$480
Price at call : $453.2 — upside +6%
Today : $485.22 — upside -1%
Expected +6% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
+2.6%
stock +3% · XLV +7%
matured Feb 11, 26
HC Wainwright & Co. ↗
Feb 11, 25
▲ Buy · 🎯$550
Price at call : $455.22 — upside +21%
Today : $485.22 — upside +13%
Expected +21% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+1.3%
stock +1% · XLV +7%
matured Feb 11, 26
Cantor Fitzgerald ↗
Jan 31, 25
▲ Overweight · 🎯$480
Price at call : $470.37 — upside +2%
Today : $485.22 — upside -1%
Expected +2% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
+0.4%
stock +0% · XLV +6%
matured Jan 31, 26
HC Wainwright & Co. ↗
Jan 31, 25
▲ Buy · 🎯$550
Price at call : $461.68 — upside +19%
Today : $485.22 — upside +13%
Expected +19% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+2.2%
stock +2% · XLV +6%
matured Jan 31, 26
Cantor Fitzgerald ↗
Jan 24, 25
▲ Overweight · 🎯$480
Price at call : $443.88 — upside +8%
Today : $485.22 — upside -1%
Expected +8% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
+7.4%
stock +7% · XLV +7%
matured Jan 24, 26
HC Wainwright & Co. ↗
Dec 20, 24
▲ Buy · 🎯$535
Price at call : $397.27 — upside +35%
Today : $485.22 — upside +10%
Expected +35% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+15.9%
stock +16% · XLV +13%
matured Dec 20, 25
▲ Buy · 🎯$586
Price at call : $493.64 — upside +19%
Today : $485.22 — upside +21%
Expected +19% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
-15.7%
stock -16% · XLV -1%
matured Nov 5, 25
Cantor Fitzgerald ↗
Nov 5, 24
▲ Overweight · 🎯$480
Price at call : $493.64 — upside -3%
Today : $485.22 — upside -1%
Expected -3% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-15.7%
stock -16% · XLV -1%
matured Nov 5, 25
HC Wainwright & Co. ↗
Oct 21, 24
▲ Buy · 🎯$600
Price at call : $478.09 — upside +25%
Today : $485.22 — upside +24%
Expected +25% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-10.8%
stock -11% · XLV -4%
matured Oct 21, 25
▲ Buy · 🎯$562
Price at call : $483 — upside +16%
Today : $485.22 — upside +16%
Expected +16% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
-13.2%
stock -13% · XLV -5%
matured Oct 17, 25
Cantor Fitzgerald ↗
Oct 8, 24
▲ Overweight · 🎯$480
Price at call : $467.97 — upside +3%
Today : $485.22 — upside -1%
Expected +3% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-11.3%
stock -11% · XLV -6%
matured Oct 8, 25
HC Wainwright & Co. ↗
Aug 5, 24
▲ Buy · 🎯$600
Price at call : $474.29 — upside +27%
Today : $485.22 — upside +24%
Expected +27% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-18.7%
stock -19% · XLV -12%
matured Aug 5, 25
Cantor Fitzgerald ↗
Aug 2, 24
▲ Overweight · 🎯$480
Price at call : $476.91 — upside +1%
Today : $485.22 — upside -1%
Expected +1% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-1.0%
stock -1% · XLV -9%
matured Aug 2, 25
Cantor Fitzgerald ↗
Jul 22, 24
▲ Overweight · 🎯$480
Price at call : $490.32 — upside -2%
Today : $485.22 — upside -1%
Expected -2% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
-2.7%
stock -3% · XLV -8%
matured Jul 22, 25
HC Wainwright & Co. ↗
Jul 19, 24
▲ Buy · 🎯$500
Price at call : $491.57 — upside +2%
Today : $485.22 — upside +3%
Expected +2% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
-6.7%
stock -7% · XLV -11%
matured Jul 19, 25
Argus Research ↗
Jun 17, 24
▲ Buy · 🎯$550
Price at call : $467.28 — upside +18%
Today : $485.22 — upside +13%
Expected +18% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.3% · +2.1% (159 calls)
-4.0%
stock -4% · XLV -9%
matured Jun 17, 25
HC Wainwright & Co. ↗
May 7, 24
▲ Buy · 🎯$462
Price at call : $410.24 — upside +13%
Today : $485.22 — upside -5%
Expected +13% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+6.0%
stock +6% · XLV -5%
matured May 7, 25
▲ Buy · 🎯$466
Price at call : $393.1 — upside +19%
Today : $485.22 — upside -4%
Expected +19% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+24.4%
stock +24% · XLV -2%
matured Apr 17, 25
HC Wainwright & Co. ↗
Apr 11, 24
▲ Buy · 🎯$462
Price at call : $400.23 — upside +15%
Today : $485.22 — upside -5%
Expected +15% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+21.0%
stock +21% · XLV -3%
matured Apr 11, 25
Cantor Fitzgerald ↗
Feb 20, 24
▲ Overweight · 🎯$440
Price at call : $419.63 — upside +5%
Today : $485.22 — upside -9%
Expected +5% · Actual +14% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
+14.5%
stock +14% · XLV +1%
matured Feb 19, 25
Cantor Fitzgerald ↗
Feb 6, 24
▲ Overweight · 🎯$440
Price at call : $419.08 — upside +5%
Today : $485.22 — upside -9%
Expected +5% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
+14.8%
stock +15% · XLV +2%
matured Feb 5, 25
HC Wainwright & Co. ↗
Feb 6, 24
▲ Buy · 🎯$457
Price at call : $416.13 — upside +10%
Today : $485.22 — upside -6%
Expected +10% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+17.4%
stock +17% · XLV +3%
matured Feb 5, 25
Cantor Fitzgerald ↗
Jan 24, 24
▲ Overweight · 🎯$440
Price at call : $429.96 — upside +2%
Today : $485.22 — upside -9%
Expected +2% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 58% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (345 calls)
+2.3%
stock +2% · XLV +4%
matured Jan 23, 25
HC Wainwright & Co. ↗
Dec 11, 23
▲ Buy · 🎯$397
Price at call : $356.29 — upside +11%
Today : $485.22 — upside -18%
Expected +11% · Actual +32% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 75% (12 calls matureds) · 📊 on Health : 52.8% · +1.2% (53 calls)
+31.7%
stock +32% · XLV +8%
matured Dec 10, 24
▲ Buy · 🎯$424
Price at call : $358.06 — upside +18%
Today : $485.22 — upside -13%
Expected +18% · Actual +37% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+37.1%
stock +37% · XLV +10%
matured Jul 23, 24
▲ Buy · 🎯$399
Price at call : $346.36 — upside +15%
Today : $485.22 — upside -18%
Expected +15% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+15.5%
stock +16% · XLV +5%
matured May 1, 24
Argus Research ↗
Mar 29, 23
▲ Buy · 🎯$350
Price at call : $312.16 — upside +12%
Today : $485.22 — upside -28%
Expected +12% · Actual +35% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.3% · +2.1% (159 calls)
+34.7%
stock +35% · XLV +14%
matured Mar 28, 24
▲ Buy · 🎯$375
Price at call : $291.6 — upside +29%
Today : $485.22 — upside -23%
Expected +29% · Actual +45% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+45.0%
stock +45% · XLV +10%
matured Feb 8, 24
▲ Buy · 🎯$373
Price at call : $323.1 — upside +15%
Today : $485.22 — upside -23%
Expected +15% · Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+34.1%
stock +34% · XLV +5%
matured Jan 30, 24
Argus Research ↗
Nov 17, 22
▲ Buy · 🎯$340
Price at call : $314.63 — upside +8%
Today : $485.22 — upside -30%
Expected +8% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.3% · +2.1% (159 calls)
+13.4%
stock +13% · XLV -4%
matured Nov 17, 23
▲ Buy · 🎯$337
Price at call : $310.5 — upside +9%
Today : $485.22 — upside -31%
Expected +9% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+18.4%
stock +18% · XLV -1%
matured Oct 21, 23
Argus Research ↗
Jun 13, 22
▲ Buy · 🎯$280
Price at call : $245.39 — upside +14%
Today : $485.22 — upside -42%
Expected +14% · Actual +39% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.3% · +2.1% (159 calls)
+39.4%
stock +39% · XLV +8%
matured Jun 13, 23
▲ Buy · 🎯$322
Price at call : $268.64 — upside +20%
Today : $485.22 — upside -34%
Expected +20% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+26.8%
stock +27% · XLV -0%
matured Apr 27, 23
▲ Buy · 🎯$325
Price at call : $287.97 — upside +13%
Today : $485.22 — upside -33%
Expected +13% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 83% (12 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+15.8%
stock +16% · XLV -3%
matured Apr 13, 23
Argus Research ↗
May 15, 20
▲ Buy · 🎯$320
Price at call : $284.13 — upside +13%
Today : $485.22 — upside -34%
Expected +13% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.3% · +2.1% (159 calls)
-23.9%
stock -24% · XLV +22%
matured May 15, 21
Argus Research ↗
Sep 28, 15
▲ Buy
Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.3% · +2.1% (159 calls)
-9.5%
stock -10% · XLV +13%
matured Sep 27, 16
Argus Research ↗
Oct 4, 12
▲ Buy
Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on VRTX : 57% (7 calls matureds) · 📊 on Health : 55.3% · +2.1% (159 calls)
+27.0%
stock +27% · XLV +23%
matured Oct 4, 13
Frequently asked questions
Should I buy Vertex Pharmaceuticals stock?
This isn't buy advice. For Vertex Pharmaceuticals, the analyst consensus is "Buy", with an average price target of $574 (+18% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Vertex Pharmaceuticals). We show the numbers — you decide.
Is it too late to buy Vertex Pharmaceuticals? How high can it go?
The most bullish analyst target on Vertex Pharmaceuticals is $617 (+27% above today's price); the average is $574. That's the upside they see. Check how reliable those analysts have actually been on Vertex Pharmaceuticals on our site before trusting it.
Is Vertex Pharmaceuticals still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 36 analysts have a real record on Vertex Pharmaceuticals, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in Vertex Pharmaceuticals? The case for and against
The arguments for and against, one by one, from the numbers: why invest in VRTX (and why hesitate).
What has Vertex Pharmaceuticals's past performance been?
Historical returns and a "how much if I had invested" calculator: VRTX performance & returns.
What is the best month to buy VRTX?
The 12 months ranked by the stock's past returns: best & worst month to buy VRTX.
BIIB 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX 
LLY